Max Robotics — Global Service Robot Directory + US Certification

About

Rifat Hasina is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus-positive oropharyngeal cancer (HPV+ OPC). Her work centers on integrating immunotherapy with response-adaptive, de-escalated treatment strategies to reduce toxicity while preserving excellent survival outcomes. In her landmark 2024 study (45 citations), she demonstrated that neoadjuvant nivolumab plus chemotherapy, followed by response-adaptive therapy, can safely de-intensify treatment for HPV+ OPC patients. She further advanced this paradigm with the TARGET-HPV trial (12 citations), evaluating neoadjuvant HB-200, a novel arenavirus-based immunotherapy targeting HPV16, combined with chemotherapy and response-stratified de-escalation. Most recently, her 2025 work (7 citations) has established the early dynamics of circulating tumor HPV DNA (ctHPV-DNA) as a promising noninvasive biomarker to guide de-escalation decisions. Through these contributions, Hasina is pioneering a precision oncology approach that spares patients unnecessary toxicity without compromising cure, positioning her at the forefront of immunotherapy and biomarker-driven de-escalation in HPV-driven head and neck cancers.